Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1
Not yet recruiting
- Conditions
- Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, RefractoryRefractory/Relapse Acute Myeloid Leukemia
- Interventions
- Drug: Ceramide NanoLiposome (Ceraxa)
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Keystone Nano, Inc
- Target Recruit Count
- 11
- Registration Number
- NCT04716452
- Locations
- ๐บ๐ธ
Penn State University Hershey Medical Center, Hershey, Pennsylvania, United States
๐บ๐ธUniversity of Virginia Cancer Center, Charlottesville, Virginia, United States
Ceramide NanoLiposome in Patients With Advanced Solid Tumors
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Keystone Nano, Inc
- Target Recruit Count
- 14
- Registration Number
- NCT02834611
- Locations
- ๐บ๐ธ
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States
๐บ๐ธMedical University of South Carolina, Hollings Cancer Center, Charleston, South Carolina, United States
๐บ๐ธUniversity of Virginia Cancer Center, Charlottesville, Virginia, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath